Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyAlaska Medicaid Benlysta prior auth Coverage | Ope…
    Ask Trek AI about this page
    CurrentAlaska MedicaidPolicy N/A

    Benlysta (belimumab) prior authorization

    Customize your policy alerts

    Sign up for all Alaska Medicaid policy alerts

    Know when Alaska Medicaid releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization criteria for Benlysta (belimumab) for treatment of systemic lupus erythematosus and lupus nephritis for Alaska Medicaid members, including age, diagnosis, prescriber, therapy, and dosing constraints.

    Policy Summary
    PayerAlaska Medicaid
    PolicyBenlysta (belimumab) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of age, diagnosis, prescriber specialty, autoantibody positivity (for SLE), and evidence of current or contraindication to standard immunosuppressive therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ages 5+minimum approved patient age
    up to 4 moinitial approval duration
    up to 12 moreauthorization
    J0490billing code

    Coverage Criteria for Benlysta (belimumab)

    Policy Summary
    PayerAlaska Medicaid
    PolicyBenlysta (belimumab) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of age, diagnosis, prescriber specialty, autoantibody positivity (for SLE), and evidence of current or contraindication to standard immunosuppressive therapy.
    SourceLink
    On This Page
    Coverage Criteria for Benlysta (belimumab)Provider Requirements and Authorization StepsBilling Codes and Dosing ExamplesDefinitions and Diagnostic CriteriaBackground

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Initial coverage criteria — Systemic Lupus Erythematosus

    Covered when ALL of the following are met for systemic lupus erythematosus

    SLE initial criteria: 1) Patient age 5–17 years and will be receiving IV infusions OR patient age ≥18 years receiving IV infusions or subcutaneous injections; 2) Diagnosis of systemic lupus erythematosus; 3) Prescribed by or in consultation with a rheumatologist, immunologist, nephrologist, neurologist, or dermatologist; 4) Autoantibody-positive SLE, defined as positive for antinuclear antibodies (ANA) and/or anti–double-stranded DNA (anti-dsDNA) antibody; 5) Patient is currently receiving standard immunosuppressive therapy (e.g., hydroxychloroquine, chloroquine, prednisone, azathioprine, methotrexate) or has a documented contraindication to standard therapy.

    Initial coverage criteria — Lupus Nephritis

    Covered when ALL of the following are met for lupus nephritis

    Lupus nephritis initial criteria: 1) Patient age 5–17 years and will be receiving IV infusions OR patient age ≥18 years receiving IV infusions or subcutaneous injections; 2) Diagnosis of lupus nephritis; 3) Prescribed by or in consultation with a nephrologist or rheumatologist; 4) ISN/RPS biopsy‑proven active Class III or IV lupus nephritis alone or in combination with Class V; 5) Patient is currently receiving standard immunosuppressive therapy (e.g., azathioprine, mycophenolate mofetil, cyclophosphamide) or has a documented contraindication to standard therapy.

    The policy specifies several usage constraints for Benlysta. The drug has not been studied in combination with other biologic agents, and its use concurrently with other biologics is not recommended. For dosing route limits, subcutaneous dosing is not approved for patients younger than 18 years of age. The FDA-labeled indications note that Benlysta is indicated for patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard therapy and for adult patients with active lupus nephritis receiving standard therapy; however, the subcutaneous formulation has age-specific approval constraints as stated above. Finally, the clinical program and trials do not provide efficacy data for patients with severe active central nervous system (CNS) lupus, and such scenarios are explicitly excluded from evaluation.

    Requests for Benlysta will be considered not medically necessary when the listed approval criteria are not met. In addition, requests will be denied if the patient is taking a concomitant biologic DMARD or Lupkynis, or if the patient has severe active central nervous system lupus.

    Provider Requirements and Authorization Steps

    Prior Authorization

    Prior authorization required; approvals tied to age, diagnosis, prescriber, antibody status, and therapy

    Benlysta (belimumab) requires prior authorization. Approval is only granted when the patient meets the listed age and administration route, has the specified diagnosis, the drug is prescribed by or in consultation with an appropriate specialist, and (for SLE) the patient is autoantibody‑positive. For both SLE and lupus nephritis, the patient must be currently receiving standard immunosuppressive therapy or have a documented contraindication to standard therapy.

    • Age and route: ages 5–17 must receive IV; age ≥18 may receive IV or subcutaneous (SLE and lupus nephritis).
    • Diagnoses: systemic lupus erythematosus (SLE) or lupus nephritis as specified in criteria.
    • Prescriber: prescribed by or in consultation with an appropriate specialist (see documentation requirements).
    • SLE-specific: autoantibody‑positive SLE required (positive ANA and/or anti‑dsDNA).
    • Therapy: must be currently receiving standard immunosuppressive therapy or have a contraindication.
    Step Therapy

    Standard immunosuppressive therapy required or documented contraindication

    Authorization requires the patient to be currently receiving standard immunosuppressive therapy appropriate to the indication, or to have a documented contraindication or intolerance to such therapy.

    • For SLE: examples include hydroxychloroquine, chloroquine, prednisone, azathioprine, or methotrexate.
    • For lupus nephritis: examples include azathioprine, mycophenolate mofetil, or cyclophosphamide.
    Documentation Required

    Required documentation: prescriber specialty, diagnosis confirmation, antibody status, and therapy details

    Submit documentation demonstrating prescriber specialty, confirmed diagnosis, and supporting clinical information at time of prior authorization request.

    • Prescriber specialty: rheumatologist, immunologist, nephrologist, neurologist, or dermatologist for SLE; nephrologist or rheumatologist for lupus nephritis (prescription or consultation).
    • Diagnosis evidence: for lupus nephritis, ISN/RPS biopsy‑proven active Class III or IV (alone or with Class V); for SLE, documentation of diagnosis.
    • Autoantibody evidence: positive ANA and/or anti‑dsDNA for autoantibody‑positive SLE.
    • Therapy evidence: documentation of current standard immunosuppressive therapy or a documented contraindication/intolerance.
    • Quantity/dosing: supply dosing schedule consistent with IV (10 mg/kg induction then every 4 weeks) or subcutaneous vial/syringe guidance as applicable; HCPCS J0490 for billing.
    Denial Risk

    Denial triggers: unmet criteria, concomitant biologics/Lupkynis, or severe active CNS lupus

    Prior authorization will be denied if the approval criteria are not met or if disallowed concomitant therapies or exclusions apply.

    • Denial if failure to meet any approval criterion.
    • Denial if the patient is taking a concomitant biologic DMARD or Lupkynis.
    • Denial if the patient has severe active central nervous system lupus.

    Billing Codes and Dosing Examples

    Covered HCPCS CodesHCPCSCovered
    J0490Benlysta (belimumab) HCPCS code as listed
    IV dosing example — 10 mg/kg schedule
    IV dosing schedule (10 mg/kg)Initiation may be approved as 10 mg/kg administered for the first 3 doses at 2-week intervals, then 10 mg/kg every 4 weeks.
    Vial presentation120 mg and 400 mg vial for intravenous (IV) infusion.
    Quantity noteQuantity limit guidance aligns with weight‑based 10 mg/kg IV dosing for initiation and maintenance.
    Subcutaneous initiation for lupus nephritis
    Subcutaneous initiation (lupus nephritis)Initiation may be approved as 8 injections in the first 28 days, then 4 injections per 28 days.
    Prefilled syringe presentation200 mg/mL prefilled autoinjector/syringe for subcutaneous use.
    Age limitation for SC dosingSubcutaneous dosing has not been evaluated and is not approved for patients younger than 18 years of age.

    Definitions and Diagnostic Criteria

    Autoantibody‑positive SLE — definition
    DefinitionSystemic lupus erythematosus with positive antinuclear antibodies (ANA) and/or anti‑double‑stranded DNA (anti‑dsDNA) antibody.
    Role in approvalAutoantibody‑positive SLE (ANA and/or anti‑dsDNA) is required for coverage approval.
    Age applicabilityApplies to patients meeting age and route criteria (ages 5–17 IV; ≥18 IV or subcutaneous).
    ISN/RPS biopsy‑proven active Class III/IV lupus nephritis — definition
    DefinitionHistologically confirmed lupus nephritis meeting International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria for active Class III or IV, alone or in combination with Class V.
    Documentation requirementISN/RPS biopsy‑proven active Class III or IV (± Class V) must be documented for approval of lupus nephritis therapy.
    Prescriber requirementMedication must be prescribed by or in consultation with a nephrologist or rheumatologist for lupus nephritis indications.

    Background

    Benlysta (belimumab) is a BLyS-specific inhibitor indicated for the treatment of patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus who are receiving standard therapy, and for adult patients with active lupus nephritis who are receiving standard therapy. The efficacy of Benlysta has not been evaluated in patients with severe active central nervous system lupus, and it has not been studied in combination with other biologics. Note that subcutaneous dosing is not approved for patients under 18 years of age.